What is it about?
Early detection of small HCC and differentiation between HCC from AC metastatic to the liver is essential for surgical pathologists, due to different treatment modalities. Immunohistochemistry plays a very important role in such conditions. In our study, we aimed to identify the diagnostic benefits of Arginase-1, FTCD& MOC-31 in the early detection of HCC in normal or cirrhotic liver, differentiation between HCC and metastatic ACs to the liver, and for early detection of small micrometastases from ACs to liver.
Featured Image
Photo by National Cancer Institute on Unsplash
Read the Original
This page is a summary of: The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver, Journal of Gastrointestinal Cancer, February 2019, Springer Science + Business Media,
DOI: 10.1007/s12029-019-00211-2.
You can read the full text:
Contributors
The following have contributed to this page
